Skip to main content
. 2018 Feb 2;8:2225. doi: 10.1038/s41598-018-20680-y

Figure 3.

Figure 3

Kaplan-Meier analyses of DFS in patients of breast cancer who received taxane-based chemotherapy or other chemotherapy. Cumulative DFS curves of breast cancer compared patients who received taxane-based chemotherapy with patients who received other chemotherapy in the overall population (a), subgroup with miR-301a negative expression status (b) and subgroup with miR-301a positive expression status (c).